Literature DB >> 22741020

DMSO exhibits similar cytotoxicity effects to thalidomide in mouse breast cancer cells.

Ece Simsek Oz1, Esra Aydemir, Kayahan Fışkın.   

Abstract

The purpose of this study was to evaluate the cytotoxic effect of thalidomide on 4T1 and 4THMpc mouse breast cancer cell lines. Mouse breast cancer cells (4T1) and cells derived from metastatic lesions (4THMpc) were treated with various doses of thalidomide [10(-2)-100 µM dissolved in dimethyl sulfoxide (DMSO) as recommended] and 1.4 µM DMSO (maximum DMSO concentration in the highest thalidomide dose) as a DMSO control against the untreated control groups. MTT was used to evaluate the cytotoxic effects of the treatments. Therefore, we investigated the role of thalidomide on apoptosis. A fluorometric EnzChek caspase-3 enzyme activity assay kit was used to evaluate the apoptotic effects of thalidomide. Thalidomide dissolved in DMSO exhibited cytotoxic effects on 4T1 and 4THMpc cells compared to the control groups incubated without any supplement. Treatment with thalidomide resulted in apoptosis of mouse breast cancer cells in a time- and dose-dependent manner as demonstrated by caspase-3 enzyme activity. However, DMSO alone suppressed cell proliferation more effectively than thalidomide. In cultured mouse breast cancer cells the inhibitory effect of thalidomide may be partially attributed to the solvent DMSO alone.

Entities:  

Year:  2012        PMID: 22741020      PMCID: PMC3362485          DOI: 10.3892/ol.2012.559

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  10 in total

1.  Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro.

Authors:  C W Spraul; C K Kaven; J K Kampmeier; G K Lang; G E Lang
Journal:  Curr Eye Res       Date:  1999-12       Impact factor: 2.424

2.  CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.

Authors:  J B Marriott; M Westby; S Cookson; M Guckian; S Goodbourn; G Muller; M G Shire; D Stirling; A G Dalgleish
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

3.  Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro.

Authors:  A L Moreira; D R Friedlander; B Shif; G Kaplan; D Zagzag
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

4.  DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture.

Authors:  N Eter; M Spitznas
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

5.  Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro.

Authors:  C Kaven; C W Spraul; N Zavazava; G K Lang; G E Lang
Journal:  Ophthalmologica       Date:  2001 Jul-Aug       Impact factor: 3.250

Review 6.  Thalidomide in cancer.

Authors:  S Singhal; J Mehta
Journal:  Biomed Pharmacother       Date:  2002-02       Impact factor: 6.529

7.  Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.

Authors:  K S Bauer; S C Dixon; W D Figg
Journal:  Biochem Pharmacol       Date:  1998-06-01       Impact factor: 5.858

Review 8.  Breast cancer: origins and evolution.

Authors:  Kornelia Polyak
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

9.  The treatment of advanced renal cell cancer with high-dose oral thalidomide.

Authors:  J Stebbing; C Benson; T Eisen; L Pyle; K Smalley; H Bridle; I Mak; F Sapunar; R Ahern; M E Gore
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

Review 10.  BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.

Authors:  Chu-Xia Deng
Journal:  Nucleic Acids Res       Date:  2006-03-06       Impact factor: 16.971

  10 in total
  6 in total

1.  Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.

Authors:  Marie Jarry; Céline Lecointre; Céline Malleval; Laurence Desrues; Marie-Thérèse Schouft; Vadim Lejoncour; François Liger; Gildas Lyvinec; Benoît Joseph; Nadège Loaëc; Laurent Meijer; Jérôme Honnorat; Pierrick Gandolfo; Hélène Castel
Journal:  Neuro Oncol       Date:  2014-06-02       Impact factor: 12.300

2.  Hydrogen Sulphide Treatment Increases Insulin Sensitivity and Improves Oxidant Metabolism through the CaMKKbeta-AMPK Pathway in PA-Induced IR C2C12 Cells.

Authors:  Xubo Chen; Xueyan Zhao; Fazhang Lan; Tao Zhou; Hua Cai; Haiying Sun; Weijia Kong; Wen Kong
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

3.  Identification of Novel and Efficacious Chemical Compounds that Disturb Influenza A Virus Entry in vitro.

Authors:  Hany Khalil; Tamer El Malah; Ahmed I Abd El Maksoud; Ibrahim El Halfawy; Ahmed A El Rashedy; Mahmoud El Hefnawy
Journal:  Front Cell Infect Microbiol       Date:  2017-06-30       Impact factor: 5.293

4.  Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.

Authors:  Simone Kumstel; Tim Schreiber; Lea Goldstein; Jan Stenzel; Tobias Lindner; Markus Joksch; Xianbin Zhang; Edgar Heinz Uwe Wendt; Maria Schönrogge; Bernd Krause; Brigitte Vollmar; Dietmar Zechner
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.240

5.  DRAQ7 as an Alternative to MTT Assay for Measuring Viability of Glioma Cells Treated With Polyphenols.

Authors:  Harcharan Kaur Rooprai; Patrick Lawrence; Sholeh Keshavarz; Pooja Yashod; Richard W Gullan; Richard P Selway; Derek Davies
Journal:  Anticancer Res       Date:  2020-10       Impact factor: 2.480

6.  Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine.

Authors:  Sebastian Rubino; Martin D Bach; Alexandra L Schober; Ian H Lambert; Alexander A Mongin
Journal:  Front Oncol       Date:  2018-05-07       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.